MX345504B - Composiciones de vesicula. - Google Patents

Composiciones de vesicula.

Info

Publication number
MX345504B
MX345504B MX2013004146A MX2013004146A MX345504B MX 345504 B MX345504 B MX 345504B MX 2013004146 A MX2013004146 A MX 2013004146A MX 2013004146 A MX2013004146 A MX 2013004146A MX 345504 B MX345504 B MX 345504B
Authority
MX
Mexico
Prior art keywords
vesicle compositions
therapeutic compound
cross
biocompatible vesicles
compound
Prior art date
Application number
MX2013004146A
Other languages
English (en)
Other versions
MX2013004146A (es
Inventor
Annapragada Ananth
Dasgupta Indrani
Tanifum Eric
srivastava Mayank
Analoui Mostafa
Original Assignee
Sensulin Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sensulin Llc filed Critical Sensulin Llc
Publication of MX2013004146A publication Critical patent/MX2013004146A/es
Publication of MX345504B publication Critical patent/MX345504B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a composiciones de vesícula que comprenden un compuesto terapéutico. Las composiciones de vesícula pueden ser capaces de liberar el compuesto terapéutico en respuesta a la presencia de un activador externo. Las composiciones de vesícula pueden comprender una pluralidad de vesículas biocompatibles. Las vesículas biocompatibles pueden comprender un compuesto terapéutico para el tratamiento de un paciente en necesidad del mismo y una o más reticulaciones entre dos o más de las vesículas biocompatibles, cada reticulación comprendiendo una porción de percepción química y una segunda porción. En algunas modalidades, el compuesto terapéutico puede ser cualquier compuesto que proporciona efectos curativos, paliativos o de otra manera benéficos para un paciente.
MX2013004146A 2011-03-02 2012-03-02 Composiciones de vesicula. MX345504B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161448556P 2011-03-02 2011-03-02
PCT/US2012/027579 WO2012119117A1 (en) 2011-03-02 2012-03-02 Vesicle compositions

Publications (2)

Publication Number Publication Date
MX2013004146A MX2013004146A (es) 2013-10-25
MX345504B true MX345504B (es) 2017-02-02

Family

ID=46758315

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004146A MX345504B (es) 2011-03-02 2012-03-02 Composiciones de vesicula.

Country Status (11)

Country Link
US (2) US8679531B2 (es)
EP (1) EP2680822B1 (es)
JP (1) JP5998158B2 (es)
KR (1) KR101845281B1 (es)
CN (2) CN107029245A (es)
AU (1) AU2012223210B2 (es)
BR (1) BR112013022170B1 (es)
CA (1) CA2822021C (es)
ES (1) ES2913069T3 (es)
MX (1) MX345504B (es)
WO (1) WO2012119117A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9801957B2 (en) 2011-04-06 2017-10-31 Ananth Annapragada Lipid-based nanoparticles
JP6130401B2 (ja) 2012-01-20 2017-05-17 アンナプラガダ,アナンス 医学画像を客観的に特徴付けるための方法および組成物
EP2727597A1 (en) * 2012-11-06 2014-05-07 Centre National de la Recherche Scientifique (CNRS) Glucose responsive hydrogel comprising pba-grafted hyaluronic acid (ha)
ES2743704T3 (es) 2014-10-08 2020-02-20 Texas Childrens Hospital Obtención de imágenes de IRM de la placa amiloide usando liposomas
CN106727328B (zh) * 2017-01-04 2020-03-13 中国药科大学 以药物-磷脂-胆固醇三元复合物为基础的脂质体制备方法
US11096893B2 (en) * 2017-06-02 2021-08-24 North Carolina State University Glucose sensitive compositions for drug delivery
CN110898032B (zh) * 2018-09-17 2021-09-14 天津大学 一种近红外光致异构纳米药物传递体系的制备方法
CN111068069B (zh) * 2018-10-18 2022-05-20 中国医学科学院药物研究所 一种免疫靶向功能性脂质体及其制备方法与用途
CN116217946B (zh) * 2023-02-09 2024-06-21 苏州大学 一种细胞外囊泡富集材料及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1996A (en) 1841-03-03 grimes
JP2874309B2 (ja) * 1990-09-13 1999-03-24 日本油脂株式会社 糖応答性高分子複合体
KR930001079B1 (ko) * 1990-07-18 1993-02-15 한국과학기술연구원 자가 방출 조절형 인슐린 제형
JPH05310844A (ja) * 1992-05-08 1993-11-22 Nippon Oil & Fats Co Ltd フェニルボロン酸基含有重合体
TW263437B (es) * 1992-09-24 1995-11-21 Takeda Pharm Industry Co Ltd
JPH06192069A (ja) * 1992-12-24 1994-07-12 Nippon Oil & Fats Co Ltd 糖応答性マイクロカプセルおよび製造方法
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
JPH07304971A (ja) * 1994-05-09 1995-11-21 Nippon Oil & Fats Co Ltd 糖応答性高分子材料
JP3270012B2 (ja) 1998-09-08 2002-04-02 富士通株式会社 ネットワークサーバ負荷検出装置、割当装置および方法
US6475750B1 (en) * 1999-05-11 2002-11-05 M-Biotech, Inc. Glucose biosensor
AU6931500A (en) * 1999-08-27 2001-03-26 M-Biotech, Inc. Glucose biosensor
JP2000086534A (ja) * 1999-10-20 2000-03-28 Nof Corp 糖応答型高分子複合体
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
WO2007124132A2 (en) * 2006-04-20 2007-11-01 University Of Utah Research Foundation Polymeric compositions and methods of making and using thereof
US20100029545A1 (en) * 2008-08-04 2010-02-04 Sumerlin Brent S Boronic acid-containing block copolymers for controlled drug delivery
KR101661746B1 (ko) * 2008-08-13 2016-09-30 캘리포니아 인스티튜트 오브 테크놀로지 캐리어 나노입자, 그리고 관련된 조성물, 방법 및 시스템

Also Published As

Publication number Publication date
MX2013004146A (es) 2013-10-25
US20120231067A1 (en) 2012-09-13
CN107029245A (zh) 2017-08-11
BR112013022170A2 (pt) 2020-09-24
US9278068B2 (en) 2016-03-08
JP2014506924A (ja) 2014-03-20
US20140227349A1 (en) 2014-08-14
JP5998158B2 (ja) 2016-09-28
CA2822021A1 (en) 2012-09-07
EP2680822A4 (en) 2014-08-20
CN103429226A (zh) 2013-12-04
AU2012223210B2 (en) 2016-12-22
KR20140074860A (ko) 2014-06-18
US8679531B2 (en) 2014-03-25
EP2680822B1 (en) 2022-02-23
BR112013022170B1 (pt) 2022-05-24
AU2012223210A1 (en) 2013-05-16
ES2913069T3 (es) 2022-05-31
EP2680822A1 (en) 2014-01-08
WO2012119117A1 (en) 2012-09-07
CA2822021C (en) 2018-01-02
KR101845281B1 (ko) 2018-04-04

Similar Documents

Publication Publication Date Title
MX345504B (es) Composiciones de vesicula.
MX2020010607A (es) Compuestos y metodos para inhibir el transporte de fosfato.
HRP20181364T1 (hr) Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci
EP2531251A4 (en) ADMINISTRATION OF LOCAL THERAPY AND LOCAL ORGAN PROTECTION
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
ZA201206425B (en) Use of erbb3 inhibitors in the treatment of treatment of triple negative and basal-like breast cancers
IL222268A (en) Preserved pyrollo-pyridines, containing pharmaceutical preparations, combined preparations containing them and their use in the preparation of medicines
GB201106750D0 (en) Novel compounds
ZA201206062B (en) Aminotetraline derivatives,pharmaceutical compositions containing them,and their use in therapy
ZA201300685B (en) Anticancer derivatives,preparation thereof and therapeutic use thereof
HK1199712A1 (en) 18-methyl-6,7-methylene-3-oxo-17-pregn-4-ene-21,17-carbolactones, pharmaceutical preparations comprising said compounds and use thereof in the treatment of endometriosis 18--67--3--17--4--2117-
CA2868551C (en) Methods and compositions for treating inflammation
MX2013004061A (es) Analogos de ciclosporina.
HK1182026A1 (en) Pharmaceutical dosage form comprising one or more antiretroviral active ingredients
DK201270677A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
SG182629A1 (en) Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
MX2013004062A (es) Analogos de ciclosporina.
EP2636666A4 (en) TRANS-2 DECENTRIC ACID DERIVATIVES AND MEDICAMENTS CONTAINING THEREOF
GB2534488A (en) Measured dose dispenser
TR201900240T4 (tr) Gece idrara çıkışları azaltmak için desmopresin.
IL223707A0 (en) N-hydroxyformamide derivative and medicament containing same
HK1178460A1 (zh) 指/趾甲變色及真菌療法
EA201590732A1 (ru) Диспергируемая таблетка
HK1177594A1 (zh) 指甲變色和真菌治療
WO2011161465A3 (en) Composition for treatment of skin

Legal Events

Date Code Title Description
HH Correction or change in general
HH Correction or change in general
FG Grant or registration